The article focuses on the new class of compounds that inhibit the same kinase as the anticancer drug imatinib through non-ATP competitive mechanism. An assay has been developed in which the cytotoxicity of compounds against cells transformed with BCR-ABL kinase. GNF2 compound does not inhibit kinases including BCR-ABL in biochemical assays. The compound also shows good pharmacokinetic behavior.